Excellent Results for Straumann in Independent Peri-Implantitis

  • Large retrospective study of dental implants in broad clinical setting: 427 patients, 1,578 implants from various manufacturers, nine-year follow-up
  • Significantly lower odds ratios for moderate/severe peri-implantitis with Straumann Tissue Level SLA implants than with the other implant systems evaluated


Results from a large independent study on peri-implantitis have shown there are substantial differences between implant systems and the occurrence of peri-implantitis, an inflammation around dental implants that leads to implant loss if not treated.

Using the national data register of the Swedish Social Insurance Agency, Dr. Jan Derks and colleagues from Gothenburg University in Sweden randomly selected 427 implant patients from a population of approximately 25,000 patients treated nine years previously by more than 800 clinicians. The selected patients were assessed for typical indicators of peri-implantitis, including bone loss, bleeding, and pocket depth around their implants.

The investigators observed that the extent of moderate/severe peri-implantitis differed between the implant systems and that the odds of developing it was more than three times higher in the patients treated with Nobel Biocare and Astra Tech Implant System implants. With some exceptions, the Nobel Biocare implants had a TiUnite® surface and the Astra Tech implants had a TiOblast® surface; all the Straumann implants were Tissue Level SLA®.

The results, which were presented at the 2015 EAO and have now been published in the Journal of Dental Research, add weight to previously reported findings showing high success rates with Straumann implants. The findings are highly relevant for dentists who base their choice of implant on independent clinical evidence.